Safreed-Harmon, Kelly
Fuster-RuizdeApodaca, Maria J.
Pastor de la Cal, Marta
Lazarus, Jeffrey V.
Funding for this research was provided by:
Gilead Sciences
Article History
Received: 20 January 2022
Accepted: 18 April 2022
First Online: 25 May 2022
Declarations
:
: The Ethics Committee of the Hospital Clínic of Barcelona, Spain, approved all research procedures in 2019. All study participants provided written informed consent.
: Not applicable.
: MJF-R and MP are members of the Spanish Interdisciplinary AIDS Society (SEISIDA) Executive Board. SEISIDA has received grants from Gilead, Janssen, MSD and ViiV, outside of the submitted work. MJF-R has provided consultancy services to Gilead, Janssen, MSD, ViiV and Theratechnologies, and has received payments for lectures or educational presentations from Gilead, Janssen, MSD and ViiV, outside of the submitted work. JVL reports grants and speaker fees from Gilead Sciences and MSD and speaker fees from AbbVie, Genfit, Intercept and ViiV, outside of the submitted work, and an institutional grant to ISGlobal from Gilead Sciences for this study.